Stereotactic Radiosurgery · Cranial
Trigeminal Neuralgia & Functional Radiosurgery
When the target is a nerve or a circuit, not a tumor — and the lesion is the therapy
Functional radiosurgery treats a physiological disorder by deliberately lesioning normal-appearing neural tissue: the trigeminal nerve for neuralgia, the thalamus for tremor, and a handful of investigational targets. Unlike tumor radiosurgery, the effect is intentionally a controlled injury, it is delayed by weeks to months, and — because it is irreversible and the dose is high — patient selection and target precision dominate everything.
Orientation
Functional radiosurgery is the radiosurgical wing of functional neurosurgery: a focused dose creates a discrete lesion in a normal-appearing structure to interrupt a pathological signal. Its great advantage is that it is incisionless and needs no anesthesia or hardware — valuable for elderly, frail, or anticoagulated patients who are poor candidates for an open or awake procedure. Its disadvantages are intrinsic: the effect is delayed (the lesion matures over weeks to months), it is irreversible and not titratable, and the high single doses sit close to dose-limiting structures. It therefore occupies specific niches rather than being first-line.
Trigeminal Neuralgia
1.Technique, dose, and outcomes
For classic, medically refractory trigeminal neuralgia, radiosurgery delivers a high single dose to the trigeminal nerve root entry zone (or a slightly more distal cisternal segment), with a maximum dose of 80–90 Gy (commonly ~80–85 Gy) prescribed to the 100% isodose through a single 4-mm collimator, with the nerve targeted a few millimeters from the brainstem. Outcomes are reported on the Barrow Neurological Institute (BNI) pain scale: initial adequate relief (BNI I–IIIb, often off or on reduced medication) in roughly 70–90% of patients, but with a characteristic latency of weeks to a few months before relief, and gradual recurrence such that durable freedom from pain is on the order of 50–60% at 3–5 years. The principal toxicity is facial numbness / sensory dysfunction in roughly 10–30%, dose-dependent and more frequent at higher maximum dose, longer treated nerve length, and after repeat treatment; the brainstem dose limit (point maximum commonly kept ≤ ~12–15 Gy) must be respected. Repeat SRS can be offered for recurrence and improves pain again in most, at the cost of higher numbness rates.
SRS is the only TN intervention that is non-ablative at the moment of treatment and creates no immediate lesion — relief is delayed precisely because it depends on a slowly evolving radiobiologic effect on the nerve. Atypical (type 2) and secondary/multiple-sclerosis-related neuralgia respond less reliably than classic type 1 pain.
2.Where SRS sits among TN options
Microvascular decompression (MVD) remains the most durable treatment and is preferred for fit patients with demonstrated neurovascular conflict; percutaneous procedures (radiofrequency rhizotomy, balloon compression, glycerol) offer rapid relief. Radiosurgery is the least invasive option and is particularly suited to elderly or comorbid patients, those on anticoagulation, or those who decline open surgery — accepting the delayed onset and somewhat lower durability in exchange for minimal procedural risk.
| Procedure | Onset | Durability / initial relief | Main trade-off |
|---|---|---|---|
| Microvascular decompression | Immediate | Most durable (~70–80% at long term) | Open posterior-fossa surgery; best with proven conflict |
| Percutaneous (RF / balloon / glycerol) | Immediate | High initial relief; recurrence over years | Sensory loss; can be repeated at bedside |
| Radiosurgery (80–90 Gy) | Delayed (weeks–months) | ~70–90% initial; ~50–60% at 3–5 yr | Latency; dose-dependent numbness; least invasive |
Radiosurgical Thalamotomy for Tremor
3.The Vim lesion without an incision
For essential tremor and tremor-dominant Parkinson disease, a high-dose lesion in the ventral intermediate (Vim) nucleus of the thalamus — typically a single ~130 Gy shot through a 4-mm collimator — can reduce contralateral tremor. It is unilateral, the benefit emerges over months as the lesion matures, and the response is somewhat less predictable per patient than with the alternatives. Its niche is the tremor patient who is not a candidate for awake DBS or for MR-guided focused ultrasound — for example, due to anticoagulation, frailty, or inability to cooperate — since radiosurgical thalamotomy requires no awake testing and no skull-density threshold. Risks include delayed perilesional edema and, uncommonly, an enlarging lesion with sensory or motor deficit. It should be set against DBS (adjustable, bilateral-capable) and MRgFUS thalamotomy (immediate, lesion-verified) covered elsewhere.
Other Functional Targets
4.Epilepsy, OCD, and the cautionary ones
Several other functional applications exist with varying evidence:
- Epilepsy — radiosurgery for mesial temporal lobe epilepsy was compared with open resection (the ROSE trial), and SRS is used for hypothalamic hamartoma and selected deep/eloquent epileptogenic lesions; its delayed effect and the need for seizure control in the interim are limitations.
- Obsessive-compulsive disorder — gamma (ventral) capsulotomy is an established radiosurgical psychiatric lesion with sham-controlled support; it is delivered within a psychiatric-surgery governance framework.
- Radiosurgical pallidotomy — largely abandoned because lesion size and effect were unpredictable without intraoperative physiological confirmation, a cautionary example of the limits of a blind, delayed lesion in functional surgery.
| Indication | Target / dose | Note |
|---|---|---|
| Trigeminal neuralgia | Root entry zone, 80–90 Gy max | ~80% initial relief; latency weeks–months; numbness dose-dependent |
| Essential / PD tremor | Vim thalamus, ~130 Gy (4 mm) | Unilateral; delayed; for non-DBS/non-FUS candidates |
| Mesial temporal epilepsy | Amygdalohippocampal complex | Compared with resection (ROSE); delayed effect |
| OCD (gamma ventral capsulotomy) | Ventral anterior internal capsule | Within psychiatric-surgery governance |
| Pallidotomy (historical) | GPi | Largely abandoned — unpredictable blind lesion |
Landmark Trials & Open Controversies
5.The dose-versus-numbness trade and the modality debate
Functional radiosurgery is built on large single-center series rather than randomized trials, and its controversies center on the trigeminal neuralgia dose and on how SRS compares with the alternatives.
| Source | What it established |
|---|---|
| Large GK TN series (Pittsburgh, Marseille, Mayo) | Initial pain relief ~70–90% (BNI); recurrence over years; dose-dependent numbness |
| Dose-comparison cohorts | Higher maximum dose (~90 vs 80 Gy) improves relief but increases sensory dysfunction |
| Repeat-SRS series | Second treatment helps most recurrences at the cost of higher numbness |
| Radiosurgical thalamotomy (tremor) series | ~130 Gy Vim lesioning reduces tremor without an incision; less predictable per patient |
Open controversies:
- Optimal maximum dose. The core trade-off is relief versus numbness: 80–85 Gy favors sensory preservation, ~90 Gy favors durability of relief — there is no consensus optimum.
- Target along the nerve. Whether to target the root entry zone or a slightly more distal cisternal segment, and how much nerve length to expose, affects both relief and numbness.
- SRS versus MVD versus percutaneous procedures. SRS is least invasive but slowest and least durable; MVD is most durable for fit patients with neurovascular conflict; the right first choice for an individual patient remains debated.
- Secondary and multiple-sclerosis-related TN. Atypical and MS-related neuralgia respond less reliably than classic type 1 pain — patient selection, not technique, drives much of the variance.
Key points
- Functional radiosurgery deliberately lesions normal tissue to interrupt a pathological signal; effect is delayed, irreversible, and not titratable.
- TN: 80–90 Gy to the root entry zone → ~80% initial relief after a weeks-to-months latency; facial numbness is the dose-dependent toxicity; MVD remains most durable for fit patients.
- Radiosurgical thalamotomy (Vim, ~130 Gy) reduces unilateral tremor over months — reserved for patients unsuitable for DBS or MRgFUS (anticoagulation, frailty, inability to cooperate).
- Other targets: epilepsy (ROSE; hypothalamic hamartoma) and gamma ventral capsulotomy for OCD; radiosurgical pallidotomy was abandoned as an unpredictable blind lesion.
- Because the lesion is blind and delayed, precise targeting and strict selection dominate outcomes.
References
- Tuleasca C, Regis J, Sahgal A, et al. Stereotactic radiosurgery for trigeminal neuralgia: a systematic review: International Stereotactic Radiosurgery Society practice guidelines. J Neurosurg. 2019;130(3):733–757. PubMed
- Regis J, Tuleasca C, Resseguier N, et al. Long-term safety and efficacy of Gamma Knife surgery in classical trigeminal neuralgia: a 497-patient historical cohort study. J Neurosurg. 2016;124(4):1079–1087. DOI
- Niranjan A, Raju SS, Kooshkabadi A, et al. Stereotactic radiosurgery for essential tremor: retrospective analysis of a 19-year experience. Mov Disord. 2017;32(5):769–777. PubMed
- Barbaro NM, Quigg M, Ward MM, et al. Radiosurgery versus open surgery for mesial temporal lobe epilepsy: the randomized, controlled ROSE trial. Epilepsia. 2018;59(6):1198–1207. PubMed
Educational synthesis for neurosurgery and radiation-oncology trainees; doses and outcomes are representative, not a treatment directive. Functional radiosurgery references verified against PubMed/DOI records during review.